Skip to main content

Risk factors for inflammatory and non-inflammatory breast cancer in North Africa

Abstract

Purpose

Studies of the etiology of inflammatory breast cancer (IBC), a rare but aggressive breast cancer, have been hampered by limited risk factor information. We extend previous studies by evaluating a broader range of risk factors.

Methods

Between 2009 and 2015, we conducted a case–control study of IBC at six centers in Egypt, Tunisia, and Morocco; enrolled were 267 IBC cases and for comparison 274 non-IBC cases and 275 controls, both matched on age and geographic area to the IBC cases. We administered questionnaires and collected anthropometric measurements for all study subjects. We used multiple imputation methods to account for missing values and calculated odds ratios (ORs) and 95% confidence intervals (CIs) using polytomous logistic regression comparing each of the two case groups to the controls, with statistical tests for the difference between the coefficients for the two case groups.

Results

After multivariable adjustment, a livebirth within the previous 2 years (OR 4.6; 95% CI 1.8 to 11.7) and diabetes (OR 1.8; 95% CI 1.1 to 3.0) were associated with increased risk of IBC, but not non-IBC (OR 0.9; 95% CI 0.3 to 2.5 and OR 0.9; 95% CI 0.5 to 1.6 for livebirth and diabetes, respectively). A family history of breast cancer, inflammatory-like breast problems, breast trauma, and low socioeconomic status were associated with increased risk of both tumor types.

Conclusions

We identified novel risk factors for IBC and non-IBC, some of which preferentially increased risk of IBC compared to non-IBC. Upon confirmation, these findings could help illuminate the etiology and aid in prevention of this aggressive cancer.

This is a preview of subscription content, access via your institution.

Abbreviations

IBC:

Inflammatory breast cancer

ER:

Estrogen receptor

BMI:

Body mass index

OR:

Odds ratio

CI:

Confidence interval

PR:

Progesterone receptor

HER2:

Human epidermal growth factor receptor 2

References

  1. 1.

    Anderson WF, Schairer C, Chen BE, Hance KW, Levine PH (2005) Epidemiology of inflammatory breast cancer (IBC). Breast Dis 22:9–23

    Google Scholar 

  2. 2.

    Morrow RJ, Etemadi N, Yeo B, Ernst M (2017) Challenging a misnomer? The role of inflammatory pathways in inflammatory breast cancer. Med Inflamm 2017:4754827. https://doi.org/10.1155/2017/4754827

    CAS  Article  Google Scholar 

  3. 3.

    Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH (2005) Trends in inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology and End Results program at the National Cancer Institute. J Natl Cancer Inst 97:966–975

    Google Scholar 

  4. 4.

    Corbex M, Bouzbid S, Boffetta P (2014) Features of breast cancer in developing countries, examples from North-Africa. Eur J Cancer 50:1808–1818

    Google Scholar 

  5. 5.

    Amiri-Kordestani L, Kamangar F, Zujewski JA (2013) Inflammatory breast cancer: yet another risk of the obesity epidemic? J Natl Cancer Inst 105:1340–1342

    Google Scholar 

  6. 6.

    Cristofanilli M (2016) Inflammatory breast cancer: a new approach. Lancet Oncol 17:544–546

    Google Scholar 

  7. 7.

    Mourali N, Muenz L, Tabbane F, Belhassen S, Bahi J, Levine PH (1980) Epidemiologic features of rapidly progressing breast cancer in Tunisia. Cancer 46:2741–2746

    CAS  Google Scholar 

  8. 8.

    Tabbane F, El May A, Hachiche M, Bahi J, Jaziri M, Cammoun M, Mourali N (1985) Breast cancer in women under 30 years of age. Breast Cancer Res Treat 6:137–144

    CAS  Google Scholar 

  9. 9.

    Boussen H, Bouzaiene H, Ben Hassouna J, Gamoudi A, Benna F, Rahal K (2008) Inflammatory breast cancer in Tunisia: reassessment of incidence and clinicopathological features. Semin Oncol 35:17–24

    Google Scholar 

  10. 10.

    Boussen H, Bouzaiene H, Ben Hassouna J, Dhiab T, Khomsi F, Benna F, Gamoudi A, Mourali N, Hechiche M, Rahal K, Levine PH (2010) Inflammatory breast cancer in Tunisia: epidemiologic and clinical trends. Cancer 116(suppl 11):2730–2735

    Google Scholar 

  11. 11.

    Lê MB, Arriagada R, Bahi J, Pfeiffer F, Cammoun M, Tabbane F, Rubino C (2006) Are risk factors for breast cancer similar in women with inflammatory breast cancer and in those with non-inflammatory breast cancer? Breast 15:355–362

    Google Scholar 

  12. 12.

    Chang S, Buxdar AU, Hursting SD (1998) Inflammatory breast cancer and body mass index. J Clin Oncol 16:3731–3735

    CAS  Google Scholar 

  13. 13.

    Moslehi R, Freedman E, Zeinomar N, Veneroso C, Levine PH (2016) Importance of hereditary and selected environmental risk factors in the etiology of inflammatory breast cancer: a case-comparison study. BMC Cancer 16:334. https://doi.org/10.1186/s12885-016-2369-z

    CAS  Article  Google Scholar 

  14. 14.

    Schairer C, Li Y, Frawley P, Graubard BI, Wellman RD, Buist DS, Kerlikowske K, Onega TL, Anderson WF, Miglioretti DL (2013) Risk factors for inflammatory breast cancer and other invasive breast cancers. J Natl Cancer Inst 105:1373–1384

    CAS  Google Scholar 

  15. 15.

    Atkinson RL, El-Zein R, Valero V, Lucci A, Bevers TB, Fouad T, Liao W, Ueno NT, Woodward WA, Brewster AM (2016) Epidemiological risk factors associated with inflammatory breast cancer subtypes. Cancer Causes Control 27:359–366

    Google Scholar 

  16. 16.

    Schairer C, Gadalla SM, Pfeiffer RM, Moore SC, Engels EA (2017) Diabetes, abnormal glucose, dyslipidemia, hypertension, and risk of inflammatory and other breast cancer. Cancer Epidemiol Biomarkers Prev 26:862–868

    CAS  Google Scholar 

  17. 17.

    Schlichting JA, Soliman AS, Schairer C, Banerjee M, Rozek LS, Schottenfeld D, Harford JB, Merajver SD (2012) Association of inflammatory and noninflammatory breast cancer with socioeconomic characteristics in the Surveillance, Epidemiology, and End Results database, 2000–2007. Cancer Epidemiol Biomarkers Prev 21:155–165

    Google Scholar 

  18. 18.

    Scott L, Mobley LR, Il’yasova D (2017) Geospatial analysis of inflammatory breast cancer and associated community characteristics in the United States. Int J Environ Res Public Health 14:404

    Google Scholar 

  19. 19.

    Khalis M, Charbotel B, Chajès V, Rinaldi S, Moskal A, Biessy C, Dossus L, Huybrechts I, Fort E, Mellas N, Elfakir S, Charaka H, Nejjari C, Romieu I, El Rhazi K (2018) Menstrual and reproductive factors and risk of breast cancer: a case–control study in the Fez region, Morocca. PLoS ONE 13(1):e0191333. https://doi.org/10.1371/journal.pone.0191333

    CAS  Article  Google Scholar 

  20. 20.

    Awatef M, Olfa G, Slim BA (2013) Impact of menstrual and reproductive factors on breast cancer risk in Tunisia: a case–control study. Med Oncol 30:480

    Google Scholar 

  21. 21.

    Awatef M, Olfa G, Imed H, Kacem M, Imen C, Rim C, Mohamed B, Slim BA (2010) Breastfeeding reduces breast cancer risk: a case–control study in Tunisia. Cancer Causes Control 21:393–397

    Google Scholar 

  22. 22.

    Soliman AS, Schairer C (2012) Considerations in setting up and conducting epidemiologic studies of cancer in middle- and low-income countries: the experience of a case-control study of inflammatory breast cancer in North Africa in the past 10 years. Cancer Med 1:338–349

    Google Scholar 

  23. 23.

    Schairer C, Hablas A, Seif Eldein IAS, Gaafar R, Rais H, Mezlini A, Ayed FB, Ayoub WB, Benider A, Tahri A, Khouchani M, Aboulazm D, Karkouri M, Eissa S, Pfeiffer RM, Gadalla SM, Swain SM, Merajver SD, Brown LM, Soliman AS (2019) Clinico-pathologic and mammographic characteristics of inflammatory and non-inflammatory breast cancer at six centers in North Africa. Breast Cancer Res Treat 176:407–417

    Google Scholar 

  24. 24.

    Raghunathan TE, Lepowski JM, van Hoewyk M, Solenberger P (2001) A multivariate technique for multiply imputing missing values using a sequence of regression models. Survey Methodol 27:85–95

    Google Scholar 

  25. 25.

    Subramanian SV, Nandy S, Irving M, Gordon D, Davey Smith G (2005) Role of socioeconomic markers and state prohibition policy in predicting alcohol consumption among men and women in India: a multilevel statistical analysis. Bull World Health Organ 83:829–836

    CAS  Google Scholar 

  26. 26.

    Bonnier P, Romain S, Dilhuydy JM, Bonichon F, Julien JP, Charpin C, Lejeune C, Martin PM, Piana L (1997) Influence of pregnancy on the outcome of breast cancer: a case–control study. Int J Cancer 72:720–727

    CAS  Google Scholar 

  27. 27.

    Nichols HB, Schoemaker MJ, Cai J, Xu J, Wright LB, Brook MN, Jones ME, Adami HO, Baglietto L, Bertrand KA, Blot WJ, Boutron-Ruault MC, Dorronsoro M, Dossus L, Eliassen AH, Giles GG, Gram IT, Hankinson SE, Hoffman-Bolton J, Kaaks R, Key TJ, Kitahara CM, Larsson SC, Linet M, Merritt MA, Milne RL, Pala V, Palmer JR, Peeters PH, Riboli E, Sund M, Tamimi RM, Tjønneland A, Trichopoulou A, Ursin G, Vatten L, Visvanathan K, Weiderpass E, Wolk A, Zheng W, Weinberg CR, Swerdlow AJ, Sandler DP (2019) Breast cancer risk after recent childbirth: a pooled analysis of 15 prospective studies. Ann Intern Med 170:22–30

    Google Scholar 

  28. 28.

    Cheraghi Z, Poorolajal J, Hashem T, Esmailnasab N, Doosti Irani A (2012) Effect of body mass index on breast cancer during premenopausal and postmenopausal periods: a meta-analysis. PLoS ONE 7(12):e51446

    CAS  Google Scholar 

  29. 29.

    De Bruijn KM, Arends LR, Hansen BE, Leeflang S, Ruiter R, van Eijck CH (2013) Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer. Br J Surg 100:1421–1429

    Google Scholar 

  30. 30.

    Klassen AC, Smith KC (2011) The enduring and evolving relationship between social class and breast cancer burden: A review of the literature. Cancer Epidemiol 35(3):217–234

    Google Scholar 

  31. 31.

    Rigby JE, Morris JA, Lavelle J, Stewart M, Gatrell AC (2002) Can physical trauma cause breast cancer? Eur J Cancer Prev 11:307–311

    CAS  Google Scholar 

  32. 32.

    Lambe M, Johansson ALV, Altman D, Eloranta S (2009) Mastitis and the risk of breast cancer. Epidemiology 20:747–751

    Google Scholar 

  33. 33.

    Zhou Y, Chen J, Li Q, Huang W, Lan H, Jiang H (2015) Association between breastfeeding and breast cancer risk: evidence from a meta-analysis. Breastfeed Med 10:175–182

    Google Scholar 

  34. 34.

    Van Laere SJ, Van den Eynden GG, Van der Auwera I, Vandenberghe M, van Dam P, Van Marck EA, van Golen KL, Vermeulen PB, Dirix LY (2006) Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling. Breast Cancer Res Treat 95:234–255

    Google Scholar 

  35. 35.

    Woodward WA (2015) Inflammatory breast cancer: unique biological and therapeutic considerations. Lancet Oncol 16(15):e568–e576. https://doi.org/10.1016/S1470-2045(15)00146-1

    CAS  Article  Google Scholar 

  36. 36.

    Alpaugh ML, Tomlinson JS, Kasraeian S, Barsky SH (2002) Cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemination of tumor emboli in inflammatory breast carcinoma. Oncogene 21:3631–3643

    CAS  Google Scholar 

  37. 37.

    Vermeulen PB, van Golen KL, Dirix LY (2010) Angiogenesis, lymphangiogenesis, growth pattern, and tumor emboli in inflammatory breast cancer: a review of current knowledge. Cancer 116(suppl 11):2748–2754

    CAS  Google Scholar 

  38. 38.

    Van der Auwera I, Van den Eynden GG, Colpaert CG, Van Laere SJ, van Dam P, Van Marck EA, Dirix LY, Vermeulen PB (2005) Tumor lymphangiogenesis in inflammatory breast carcinoma: a histomorphometric study. Clin Cancer Res 11:7637–7642

    Google Scholar 

  39. 39.

    Kleer CG, van Golen KL, Merajver SD (2000) Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res 2:423–429

    CAS  Google Scholar 

  40. 40.

    Angelo LS, Kurzrock (2007) Vascular endothelial growth factor and its relationship to inflammatory mediators. Clin Cancer Res 13:2825–2830

    CAS  Google Scholar 

  41. 41.

    Kolb R, Sutterwala FS, Weizhou Z (2016) Obesity and cancer: inflammation bridges the two. Curr Opin Pharmacol 29:77–89

    CAS  Google Scholar 

  42. 42.

    Donath MY, Shoelson SE (2011) Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 11:98–107

    CAS  Google Scholar 

  43. 43.

    Ruiz R, Herrero C, Strasser-Weippl K, Touya D, St Louis J, Bukowski A, Goss PE (2017) Epidemiology and pathophysiology of pregnancy-associated breast cancer: a review. Breast 35:136–141

    Google Scholar 

  44. 44.

    Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, Li Y, Wang X, Zhao L (2017) Inflammatory responses and inflammation-associated diseases in organs. Oncotarget 9:7204–7218

    Google Scholar 

  45. 45.

    Nishimura S, Maeno N, Matsuo K, Nakajima T, Kitajima I, Saito H, Maruyama I (2002) Human lactiferous mammary gland cells produce vascular endothelial growth factor (VEGF) and express the VEGF receptors, Flt-1 and KDR/Flk-1. Cytokine 18:191–198

    CAS  Google Scholar 

  46. 46.

    Anderson KN, Schwab RB, Martinez ME (2014) Reproductive risk factors and breast cancer subtypes: a review of the literature. Breast Cancer Res Treat 144:1–10

    Google Scholar 

  47. 47.

    Suzuki R, Orsini N, Saji S, Key TJ, Wolk A (2009) Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status: a meta-analysis. Int J Cancer 124:698–712

    CAS  Google Scholar 

Download references

Acknowledgements

We are very grateful to the women who participated in this study. We also thank the following individuals for their important contributions to the study, including identifying, enrolling, and interviewing study subjects, study management, data keying, logistical support, and translation: Tanta Cancer Center/Gharbiah Cancer Society: Dr. Salwas Samir, Dr. Eman Sobhy, Dr. Mohammed El Kholy, Mr. Khalid Dabboos, Ms. Hanaa Elmenshawy; NCI-Cairo: Dr. Gamal Amira, Dr. Heba Mohamed El Leethy, Dr. Usama Farouk El Nagar, Ms. Walaa Emara, Ms. Magda Hassan, Ms. Hanan Mabrouk; Tunisia: Dr. Karima Mrad, Dr. Dalenda Hentati, Dr. Houda Belfekih, Dr. Nesrine Chraiet, Dr. Amira Daldoul, Dr. Mouna Ayadi, Dr. Bassem Alani, Ms. Leila Fadhlaoui, Ms. Neila Ben Hassen; Ibn Rochd Oncology Center: Prof. Nadia Benchakroun, Dr. Hoda Eddakaoui, Dr. Myriam Hatime, Dr. Soufya Majdoul, Dr. Fadwa Qachach, Dr. Basma Billal, Dr. Hajar Kouss, Dr. Noureddine Matar, Dr. Iman Meziane, Dr. Sara Belkheiri, Dr. Karima Bendahhou, Dr. Majdouline Khounigere, Dr. Ibrahim Khalil Ahmadaye; University Hospital Center Mohammed VI, Marrakech: Dr. Mariam Affane, Dr. Sana Zabroug, Dr. Mouna Darfaoui, Mr. Hicham Jabraoui; IMS (data management and keying): Ms. Leslie Carroll, Mr. Bob Banks, Ms. Bette Griffith, Dr. Carol Giffen, Mr. Michael Spriggs; NCI-USA (logistical support): Mr. David Check, Ms. Prisca N. Fall; Westat (translation): Dr. Susan Crystal-Mansour, and Ms. Jerelyn Bouic. The National Institutes of Health National Library of Medicine Interaction Tool used in this work was developed by the Communications Engineering Branch of the National Library of Medicine (Mr. Rodney Long and Mr. Leif Neve). We would also like to thank the Cancer Epidemiology Education in Special Populations (CEESP) Program students who assisted in different parts of the study during their CEESP projects.

Funding

This work was supported by the National Cancer Institute at the National Institutes of Health Intramural Research Program (C.S., R.M.P., S.M.G.), the Breast Cancer Research Foundation (S.D.M.), the Metavivor Foundation (S.D.M.), and CEESSP Program (Grant R25 CA112383) (A.S.S.).

Author information

Affiliations

Authors

Corresponding author

Correspondence to Ruth M. Pfeiffer.

Ethics declarations

Conflict of interest

Sandra Swain reports receiving honoraria from Novartis, personal fees from Cardinal Health, Daiichi-Sankyo, Eli Lilly & Co., Genentech/Roche, Genomic Health, Inivata, Peiris Pharmaceuticals, Tocagen; research support from Genentech; travel and accommodations from Caris Centers of Excellence, Daiichi-Sankyo, Eli Lilly & Co., Genentech/Roche, NanoString Technologies; and remuneration from AstraZeneca for participation on OlympiA IDMC. The other authors declare they have no conflicts of interest.

Ethical approval

All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional research committees.

Informed consent

Informed consent was obtained from all study participants.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 65 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Schairer, C., Hablas, A., Eldein, I.A.S. et al. Risk factors for inflammatory and non-inflammatory breast cancer in North Africa. Breast Cancer Res Treat 184, 543–558 (2020). https://doi.org/10.1007/s10549-020-05864-3

Download citation

Keywords

  • Inflammatory breast cancer
  • Risk factor
  • Egypt
  • Tunisia
  • Morocco